SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 13,775.80 |
Enterprise Value ($M) | 30,915.50 |
Book Value ($M) | 20,467.40 |
Book Value / Share | 17.23 |
Price / Book | 0.67 |
NCAV ($M) | -14,242.00 |
NCAV / Share | -11.99 |
Price / NCAV | -0.97 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | 0.00 |
Return on Assets (ROA) | 0.00 |
Return on Equity (ROE) | 0.00 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 1.22 |
Current Ratio | 1.67 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 12,976.10 |
Assets | 47,685.50 |
Liabilities | 27,218.10 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 15,426.90 |
Operating Income | 1,999.40 |
Net Income | 54.70 |
Earnings Per Share Basic And Diluted | n/a |
Earnings Per Share Basic | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 2,799.60 |
Cash from Investing | -764.10 |
Cash from Financing | -2,301.90 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Vanguard Group Inc | 11.86 | -4.73 | |
13G | Davis Selected Advisers | 5.20 | ||
13G/A | State Street Corp | 5.17 | 0.11 | |
13G/A | BlackRock Inc. | 7.70 | -0.94 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
1,349,504 | 7,808,288 | 17.28 | |
1,047,420 | 6,625,199 | 15.81 | |
590,740 | 3,533,568 | 16.72 | |
668,964 | 4,332,218 | 15.44 | |
(click for more detail) |
Similar Companies | |
---|---|
VIRX – Viracta Therapeutics, Inc. | VOR – Vor Biopharma Inc. |
VRTX – Vertex Pharmaceuticals Incorporated | VTYX – Ventyx Biosciences, Inc. |
VYGR – Voyager Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io